Company intelligence / Profile preview

Seanergy Pharma

Rehovot, Israel

Ownership: Private
Development stage: Other

Overview

Seanergy Pharma is a clinical-stage biotechnology company developing a new category of topical therapeutics for inflammatory skin conditions. Their technology platform is based on the discovery of a synergistic mechanism between anti-inflammatory active pharmaceutical ingredients (APIs) and sulphated polysaccharides (SPS) extracted from microalgae (Porphyridium cruentum). The lead candidate, SNG100, a combination of hydrocortisone and SPS, has completed a Phase 1/2a proof-of-concept study demonstrating safety, tolerability, and signs of efficacy in patients with moderate atopic dermatitis.

Therapeutic areas: Dermatology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Mii LabsWeizmann Institute of ScienceHadassah University Hospital

Beyond the preview

Go deeper on Seanergy Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seanergy Pharma.

Explore the full profile